Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accounts Payables: 2020-2024

Historic Accounts Payables for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $12.0 million.

  • Maravai Lifesciences Holdings' Accounts Payables fell 15.76% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 15.76%. This contributed to the annual value of $12.0 million for FY2024, which is 11.45% up from last year.
  • Maravai Lifesciences Holdings' Accounts Payables amounted to $12.0 million in FY2024, which was up 11.45% from $10.7 million recorded in FY2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Accounts Payables peaked at $718.2 million during FY2022, and registered a low of $8.2 million during FY2021.
  • Its 3-year average for Accounts Payables is $247.0 million, with a median of $12.0 million in 2024.
  • In the last 5 years, Maravai Lifesciences Holdings' Accounts Payables surged by 8,707.95% in 2022 and then tumbled by 98.51% in 2023.
  • Maravai Lifesciences Holdings' Accounts Payables (Yearly) stood at $8.2 million in 2020, then dropped by 0.21% to $8.2 million in 2021, then skyrocketed by 8,707.95% to $718.2 million in 2022, then plummeted by 98.51% to $10.7 million in 2023, then grew by 11.45% to $12.0 million in 2024.